SuperworthBiocryst Pharmaceuticals shares outstanding BCRX
Diluted shares outstanding, averaged over each quarter, from 2014.
- Latest quarter, to Jun 30, 2026
- 265.2M
- On a year earlier
- +20.6%
- more shares
Biocryst Pharmaceuticals had 265.2M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 20.6% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 219.3M | +6% |
| FY2024 | 207.4M | +3% |
| FY2023 | 201.4M | +8% |
| FY2022 | 186.9M | +3% |
| FY2021 | 181.8M | +3% |
| FY2020 | 176.6M | +35% |
| FY2019 | 131.3M | +20% |
| FY2018 | 109.8M | +12% |
| FY2017 | 98.4M | +33% |
| FY2016 | 73.8M | +1% |
| FY2015 | 73.3M | +2% |
| FY2014 | 71.9M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 265.2M | +21% | |
| Q1 FY26 | 242.3M | +13% | |
| Q4 FY25 | 219.3M | +6% | |
| Q3 FY25 | 219.9M | +6% | |
| Q2 FY25 | 219.9M | +7% | |
| Q1 FY25 | 215.3M | +4% | |
| Q4 FY24 | 207.4M | +3% | |
| Q3 FY24 | 206.9M | +9% | |
| Q2 FY24 | 206.4M | +9% | |
| Q1 FY24 | 206.1M | +9% | |
| Q4 FY23 | 201.4M | +8% | |
| Q3 FY23 | 189.6M | +2% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Biocryst Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.